Integrated Treatment for Opioid Use Disorder and PTSD

Description

This study will test a therapy intervention, HOPE, for individuals with opioid use disorder and posttraumatic stress disorder. Interested individuals will need to be taking medications for opioid use disorder (e.g., suboxone, naltrexone, methadone). Interested participants will complete a 10-12 week therapy, and be asked to complete surveys.

Conditions

Opioid Use Disorder, Posttraumatic Stress Disorder (PTSD)

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will test a therapy intervention, HOPE, for individuals with opioid use disorder and posttraumatic stress disorder. Interested individuals will need to be taking medications for opioid use disorder (e.g., suboxone, naltrexone, methadone). Interested participants will complete a 10-12 week therapy, and be asked to complete surveys.

Integrated Treatment for Co-Occurring Opioid Use Disorder and Posttraumatic Stress Disorder

Integrated Treatment for Opioid Use Disorder and PTSD

Condition
Opioid Use Disorder
Intervention / Treatment

-

Contacts and Locations

Charleston

Medical University of South Carolina, Charleston, South Carolina, United States, 29403

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Any gender; any race or ethnicity; aged 18-70 years old.
  • * English-speaking
  • * Meet DSM-5 diagnostic criteria for OUD.
  • * Meet DSM-5 diagnostic criteria for PTSD and have some memory of their index traumatic event.
  • * Must be maintained on a stable dose of medication for OUD for at least 1 month.
  • * Participants taking psychotropic medications will be required to be maintained on a stable dose for at least 1 month before study initiation.
  • * Participants presenting with psychiatric contraindications (e.g., unmanaged psychosis or mania, or bipolar) will be excluded and referred clinically.
  • * Participants considered an immediate suicide risk, with current suicidal ideation and a plan of intent, or displaying other high-risk behaviors (i.e., MOUD refusal, risky fentanyl use, etc.), as determined by the PI and study team. These individuals will complete a safety plan and be referred for treatment.
  • * Participants meeting DSM-5 criteria for a concurrent, non-opioid, substance use disorder and who report that the other substance is their primary substance of use. These participants will be referred clinically for treatment.
  • * Participants enrolled in ongoing evidence-based psychotherapy for substance use disorders or PTSD outside of medications for OUD and standard psychotherapy groups in treatment programs.
  • * Medical problems requiring immediate and intensive treatment, such as unstable or symptomatic end stage liver disease.

Ages Eligible for Study

18 Years to 70 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Medical University of South Carolina,

Tanya Saraiya, PhD, PRINCIPAL_INVESTIGATOR, Medical University of South Carolina

Study Record Dates

2027-08